Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
NCT00022659Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2002
- Primary completion
- Mar 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in ovarian epithelial cancer, primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Started Apr 2002; status: completed.
02
Drugs
bevacizumab
03
Conditions
ovarian epithelial cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00022659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022659.